NCT05934955View on ClinicalTrials.gov

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

September 25, 2023

Study Completion Date

October 2, 2023

Conditions
Healthy
Interventions
DRUG

BI 1839100

BI 1839100

DRUG

Placebo matching BI 1839100

Placebo matching BI 1839100

Trial Locations (1)

130-0004

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05934955 - A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003) | Biotech Hunter | Biotech Hunter